IR-News

AUSSENDER



DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
Ansprechpartner: Marco Scheidler
Tel.: +49 3641 31000-30
E-Mail: ms@dewb.de

FRüHERE MELDUNGEN

14.07.2015 - 14:05 | DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
14.07.2015 - 14:05 | DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
30.06.2015 - 09:44 | DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
29.05.2015 - 11:10 | DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
29.05.2015 - 11:10 | DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
pta20151020005
Public disclosure of inside information according to article 17 MAR

DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG: NOXXON Pharma Announces Intention to Launch an Initial Public Offering

on Euronext Amsterdam and Euronext Paris


Jena (pta005/20.10.2015/07:20) - DEWB investment holding NOXXON Pharma N.V., a clinical-stage biopharmaceutical company primarily focused on cancer treatment development, announces today its intention to raise new funds through an Initial Public Offering ("IPO" or the "Offering") and the listing of its ordinary shares (the "Shares") on Euronext Amsterdam and Euronext Paris.

The intended Offering would consist of newly issued Shares only. NOXXON intends to seek admission to listing and trading of the Shares on Euronext Amsterdam and Euronext Paris. The Offering is expected to be available to institutional investors and retail investors in the Netherlands and France, and to institutional investors in various other jurisdictions. The Offering and the listing, and their timing, are subject to, among other matters, market conditions. Kempen & Co N.V. is acting as Sole Global Coordinator and, together with Gilbert Dupont SNC as the Joint Bookrunners, for the Offering.

NOXXON intends to use the net proceeds of the Offering for the further clinical development of its lead product candidate NOX-A12 in various oncology indications, advancement of its pre-clinical pipeline and discovery efforts to identify new immuno-oncology and tumor microenvironment-targeting product candidates, completion of the on-going NOX-H94 trial and general corporate purposes.

(end)
emitter: DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
Fraunhoferstraße 1
07743 Jena
Germany
contact person: Marco Scheidler
phone: +49 3641 31000-30
e-mail: ms@dewb.de
website: www.dewb.de
stock exchanges: basic board in Frankfurt, free market in Munich, free market in Stuttgart; open market in Berlin
ISIN(s): DE0008041005 (share)
|
|
98.373 Abonnenten
|
193.894 Meldungen
|
80.027 Pressefotos
Top